2. Webb T.R., Slavish J., George R.E., Look A.T., Xue L., Jiang Q., Cui X., Rentrop W.B., Morris S.W. (2009) Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther;9:331–356. 3. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishika- wa S., Fujiwara S. et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nat- ure;448:561–566. 4. Mosse Y.P., Wood A., Maris J.M. (2009) Inhibition of ALK signal- ing for cancer therapy. Clin Cancer Res;15:5609–5614. 5. McDermott U., Iafrate A.J., Gray N.S., Shioda T., Classon M., Maheswaran S., Zhou W. et al. (2008) Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res;68:3389–3395. 6. Christensen J.G., Zou H.Y., Arango M.E., Li Q., Lee J.H., McDon- nell S.R., Yamazaki S., Alton G.R., Mroczkowski B., Los G. (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther;6:3314–3322. 7. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., Ou S.H. et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med;363:1693–1703. 8. Butrynski J.E., D'Adamo D.R., Hornick J.L., Dal Cin P., Antonescu C.R., Jhanwar S.C., Ladanyi M. et al. (2010) Crizotinib in ALK- rearranged inflammatory myofibroblastic tumor. N Engl J Med;363:1727–1733. 9. Azam M., Latek R.R., Daley G.Q. (2003) Mechanisms of autoinhi- bition and STI-571 ⁄ imatinib resistance revealed by mutagenesis of BCR-ABL. Cell;112:831–843. 10. Bradeen H.A., Eide C.A., O'Hare T., Johnson K.J., Willis S.G., Lee F.Y., Druker B.J., Deininger M.W. (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high effi- cacy of drug combinations. Blood;108:2332–2338. 11. Galkin A.V., Melnick J.S., Kim S., Hood T.L., Li N., Li L., Xia G. et al. (2007) Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA;104:270–275. 12. Choi Y.L., Takeuchi K., Soda M., Inamura K., Togashi Y., Hatano S., Enomoto M. et al. (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res;68:4971–4976. 13. George R.E., Sanda T., Hanna M., Frohling S., Luther W. 2nd, Zhang J., Ahn Y. et al. (2008) Activating mutations in ALK pro- vide a therapeutic target in neuroblastoma. Nature;455:975–978. 14. Zou H.Y., Li Q., Lee J.H., Arango M.E., McDonnell S.R., Yamazaki S., Koudriakova T.B., Alton G., Cui J.J., Kung P.P., Nambu M.D., Los G., Bender S.L., Mroczkowski B., Christensen J.G. (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res;67:4408–4417. 15. Katayama R., Khan T.M., Benes C., Lifshits E., Ebi H., Rivera V.M., Shakespeare W.C., Iafrate A.J., Engelman J.A., Shaw A.T. Crizotinib-Resistant EML4-ALK Mutations (2011) Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA;108:7535–7540. 16. Jabbour E., Cortes J., O'Brien S., Giles F., Kantarjian H. (2007) New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hema- tol;44:S25–S31. 17. Sakamoto H., Tsukaguchi T., Hiroshima S., Kodama T., Kobayashi T., Fukami Takaaki A., Oikawa N., Tsukuda T., Ishii N., Aoki Y. (2011) CH5424802, a selective alk inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell;19:679–690. 18. Lovly C.M., Heuckmann J.M., de Stanchina E., Chen H., Thomas R.K., Liang C., Pao W. (2011) Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res;71:4920–4931. 19. Bossi R.T., Saccardo M.B., Ardini E., Menichincheri M., Rusconi L., Magnaghi P., Orsini P., Avanzi N., Borgia A.L., Nesi M., Bandi- era T., Fogliatto G., Bertrand J.A. (2010) Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry;49:6813–6825. 20. Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A., de Pontual L., Combaret V., Raynal V. et al. (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature;455:967–970. 21. Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L., Soda M., Kikuchi A., Igarashi T., Nakagawara A., Hayashi Y., Mano H., Ogawa S. (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature;455:971–974. 22. Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakaj- ima T., Yatabe Y., Takeuchi K., Hamada T., Haruta H., Ishikawa Y., Kimura H., Mitsudomi T., Tanio Y., Mano H. (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med;363:1734–1739. 23. Sasaki T., Okuda K., Zheng W., Butrynski J., Capelletti M., Wang L., Gray N.S., Wilner K., Christensen J.G., Demetri G., Shapiro G.I., Rodig S.J., Eck M.J., Janne P.A. (2010) The neuroblastoma associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK translocated cancers. Cancer Res;70:10038–10043. Supporting Information Additional Supporting Information may be found in the online ver- sion of this article: Figure S1. Chemical structure of crizotinib and TAE684. Figure S2. Impact of L1196M on anti-ALK activity of crizotinib and TAE684. Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article. Chem Biol Drug Des 2011; 78: 999–1005 1005